1 Introduction
1.1 What Is This Report About?
1.2 Hematological Disorders Market Segmentation
1.3 Definitions of Markets Covered in the Report
2 Hematological Disorders Market, United States
2.1 Hematological Disorders Market, United States, Revenue ($m), 2024-2036
2.1.1 Hematology Tests Market, United States, Revenue ($m), by Segment, 2024-2036
2.1.2 Hemostasis Tests Market, United States, Revenue ($m), by Segment, 2024-2036
2.2 Hematological Disorders Market, United States, Volume (Units), 2024-2036
2.2.1 Hematology Tests Market, United States, Volume (Units), by Segment, 2024-2036
2.2.2 Hemostasis Tests Market, United States, Volume (Units), by Segment, 2024-2036
2.3 Hematological Disorders Market, United States, Average Price ($), 2024-2036
2.4 Hematological Disorders Market, United States, Company Share by Revenue ($m), 2025
3 Hematological Disorders Market Pipeline Products
3.1 Hematological Disorders Market Pipeline Products
3.2 Hematological Disorders - Pipeline Products by Stage of Development
3.3 Hematological Disorders - Pipeline Products by Segment
3.4 Hematological Disorders - Pipeline Products by Territory
3.5 Hematological Disorders - Pipeline Products by Regulatory Path
3.6 Hematological Disorders - Pipeline Products by Estimated Approval Date
4 Overview of Key Companies in United States, Hematological Disorders Market
4.1 Abbott Laboratories
4.1.1 Company Overview
4.2 Roche Diagnostics International Ltd
4.2.1 Company Overview
4.3 Sysmex Corp
4.3.1 Company Overview
4.4 Siemens AG
4.4.1 Company Overview
4.5 Instrumentation Laboratory Co
4.5.1 Company Overview
4.6 Diagnostica Stago SAS
4.6.1 Company Overview
4.7 Beckman Coulter Inc
4.7.1 Company Overview
4.8 Quidel Corp
4.8.1 Company Overview
4.9 Radiometer Medical ApS
4.9.1 Company Overview
4.10 Thermo Fisher Scientific Inc
4.10.1 Company Overview
5 Recent Developments
5.1 Corporate Communications
5.1.1 May 18, 2026: Texas Children’s Faculty Receive More Than $5.6M in Research Grants
5.1.2 Nov 20, 2025: Quanterix Announces Board and Leadership Changes
5.1.3 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors
5.1.4 Nov 12, 2025: Pillar Biosciences Launches New NGS Panel for Tumor Profiling of Lymphoid Malignancies
5.1.5 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
5.1.6 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
5.1.7 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager
5.1.8 Oct 29, 2025: Regenerative Medicine Also Known As Stem Cell Therapy
5.1.9 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
5.1.10 Oct 21, 2025: Plus Therapeutics Provides Update on CNSide Diagnostic Platform Launch
5.1.11 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
5.1.12 Oct 08, 2025: Virogates A/S Announces Public Tender Offer to Shareholders
5.1.13 Oct 01, 2025: Predicta Biosciences Raises $23.4M to Expand Diagnostic Platform for Blood Cancers
5.1.14 Oct 01, 2025: Castle Biosciences’ Derek Maetzold Named CEO of the Year by The CEO Magazine
5.1.15 Sep 23, 2025: Pictor Secures Funding for U.S. Expansion Through Proteomics Solutions
5.1.16 Sep 15, 2025: Mdxhealth Completes Acquisition of Exosome Diagnostics from Bio-Techne
5.2 Government and Public Interest
5.2.1 Nov 24, 2025: Adaptive Biotechnologies to Present Nearly 90 Abstracts Featuring clonoSEQ MRD Testing at 67th ASH Meeting
5.2.2 Nov 13, 2025: Telo Genomics to Present Individual-Cell Risk Assessment MRD Technology at Myeloma Canada Summit
5.3 Other Significant Developments
5.3.1 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
5.3.2 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors
5.3.3 Nov 05, 2025: YD Bio and EG BioMed Expand U.S. Access to OkaiDx for Breast Cancer Monitoring
5.3.4 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth
5.3.5 Oct 30, 2025: Refurbished Vs New Immulite 2000Xpi: Which Is Better for Your Lab
5.3.6 Oct 21, 2025: Plus Therapeutics Provides Update on CNSide Diagnostic Platform Launch
5.3.7 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
5.3.8 Oct 08, 2025: Virogates A/S Announces Public Tender Offer to Shareholders
5.3.9 Sep 19, 2025: NDSU Annual Research Awards Total $93.5 Million
5.4 Product News
5.4.1 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV
5.4.2 Nov 24, 2025: Adaptive Biotechnologies to Present Nearly 90 Abstracts Featuring clonoSEQ MRD Testing at 67th ASH Meeting
5.4.3 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months
5.4.4 Nov 13, 2025: Telo Genomics to Present Individual-Cell Risk Assessment MRD Technology at Myeloma Canada Summit
5.4.5 Nov 13, 2025: Single Digit Parts Per Million Detection of Molecular Residual Disease Through Integrated Tumor-Informed Whole-Genome Sequencing Analysis
5.4.6 Nov 05, 2025: YD Bio and EG BioMed Expand U.S. Access to OkaiDx for Breast Cancer Monitoring
5.4.7 Oct 30, 2025: Refurbished Vs New Immulite 2000Xpi: Which Is Better for Your Lab
5.4.8 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder
5.4.9 Oct 21, 2025: Plus Therapeutics Provides Update on CNSide Diagnostic Platform Launch
5.4.10 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers
5.4.11 Oct 09, 2025: American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at 2025 Meeting
5.4.12 Oct 02, 2025: Hologic Receives FDA Clearance And CE Mark For Automated Molecular Tests To Detect Infectious Gastroenteritis
5.4.13 Oct 01, 2025: Predicta Biosciences Raises $23.4M to Expand Diagnostic Platform for Blood Cancers
5.5 Research And Development
5.5.1 Feb 04, 2026: Advancing Early Detection for Kidney Disease in Sickle Cell
5.6 Strategy And Business Planning
5.6.1 Mar 13, 2026: University Hospitals to Build Modern Pathology Laboratory
5.6.2 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group
5.6.3 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics
5.6.4 Oct 14, 2025: START, Together With HM Hospitales, Inaugurates Spain’s First Pediatric Onco-Hematology Clinical Research Unit
5.6.5 Oct 02, 2025: AIxMed And Biopticka Laborator Announce Strategic Collaboration On AI-Cytology In Europe
5.6.6 Sep 23, 2025: Pictor Secures Funding for U.S. Expansion Through Proteomics Solutions
6 Appendix
6.1 Research Methodology
6.1.1 Coverage
6.1.2 Secondary Research
6.1.3 Primary Research
6.1.4 Market Modeling and Forecasting
6.1.5 Company Share Analysis
6.1.6 Benchmarking
6.2 the Analyst Consulting
6.3 Contact Us
6.4 Disclaimer
List of Tables
Table 1: Hematological Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 2: Hematology Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 3: Hemostasis Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Table 4: Hematological Disorders Market, United States, Volume (Units), 2024-2036
Table 5: Hematology Tests Market, United States, Volume (Units), 2024-2036
Table 6: Hemostasis Tests Market, United States, Volume (Units), 2024-2036
Table 7: Hematological Disorders Market, United States, Average Price ($), 2024-2036
Table 8: Hematological Disorders Market, United States, Company Share by Revenue ($m), USD Constant, 2025
Table 9: Hematological Disorders Market Pipeline Products
Table 10: Hematological Disorders - Pipeline Products by Stage of Development
Table 11: Hematological Disorders Companies - Pipeline Products by Stage of Development
Table 12: Hematological Disorders - Pipeline Products by Segment
Table 13: Hematological Disorders - Pipeline Products by Territory
Table 14: Hematological Disorders - Pipeline Products by Regulatory Path
Table 15: Hematological Disorders - Pipeline Products by Estimated Approval Date
Table 16: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
List of Figures
Figure 1: Hematological Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 2: Hematology Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 3: Hemostasis Tests Market, United States, Revenue ($m), USD Constant, 2024-2036
Figure 4: Hematological Disorders Market, United States, Volume (Units), 2024-2036
Figure 5: Hematology Tests Market, United States, Volume (Units), 2024-2036
Figure 6: Hemostasis Tests Market, United States, Volume (Units), 2024-2036
Figure 7: Hematological Disorders Market, United States, Company Share (%), 2025
Figure 8: Hematological Disorders - Pipeline Products by Stage of Development
Figure 9: Hematological Disorders - Pipeline Products by Segment
Figure 10: Hematological Disorders - Pipeline Products by Territory
Figure 11: Hematological Disorders - Pipeline Products by Regulatory Path
Figure 12: Hematological Disorders - Pipeline Products by Estimated Approval Date
